Tenderwize
Wróć do wyszukiwania

Non-exclusive Ibuprofen Discount Agreement

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Feb 28, 2027 · 185 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ibuprofen (ATC-Code nach WHO: M01AE01)

40/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

40 / 100

Złożoność

30 / 100

Czynniki ryzyka

Unknown demand and no guaranteed minimum volumes; actual revenue is highly uncertain.

Agreement may be terminated early if exclusive discount agreements are signed by AOK PLUS.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Supply of Ibuprofen film tablets (ATC M01AE01) under a non-exclusive discount agreement
  • Pharmaceutical companies must be eligible under § 130a Abs. 8 SGB V and § 4 Abs. 18 AMG
Pokaż pełne podsumowanie

Non-exclusive drug discount agreement (Rabattvereinbarung) for Ibuprofen (ATC M01AE01) film tablets under an Open House model with AOK PLUS. The agreement is open to all qualified pharmaceutical companies during the participation period. No guaranteed minimum quantities, no exclusive supply, and individual negotiations are not conducted. The agreement ends 28 February 2027, with possible early termination if exclusive agreements are concluded. This publication is for transparency and not a formal public procurement under EU directives.

Ryzyka

Unknown demand and no guaranteed minimum volumes; actual revenue is highly uncertain.

Agreement may be terminated early if exclusive discount agreements are signed by AOK PLUS.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical company as defined in § 4 Abs. 18 AMG with respect to the offered drugs

Eligibility

  • Submit declaration of no exclusion grounds (§§ 123, 124 GWB)

Administrative

  • Submit declaration regarding EU Russia sanctions (Art. 5k of Regulation (EU) 2022/576)

Kryteria udzielenia

Lot 1

No award criteria specified; this is a non-competitive Open House model, not a traditional tender.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive Ibuprofen Discount Agreement

Conclusion of non-exclusive discount agreements for prescription drugs with active ingredient Ibuprofen (ATC M01AE01) in film tablet form. Open House model: any interested pharmaceutical company can join if they meet the conditions. No minimum purchase quantities, unknown demand dependent on prescription behavior.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

May 2025 - Feb 2027

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria specified; this is a non-competitive Open House model, not a traditional tender.

Termin

Expired May 05, 2025

Szczegóły zamówienia

Data publikacji
13 Feb 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
102408-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3